Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
70.13
-3.47 (-4.71%)
At close: Apr 28, 2026, 4:00 PM EDT
70.49
+0.36 (0.52%)
After-hours: Apr 28, 2026, 4:21 PM EDT
Arrowhead Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Arrowhead Pharmaceuticals stock have an average target of 83.4, with a low estimate of 17 and a high estimate of 110. The average target predicts an increase of 18.92% from the current stock price of 70.13.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Arrowhead Pharmaceuticals stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 6 | 6 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 4 | 3 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 11 | 11 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades $78 → $100 | Hold → Buy | Upgrades | $78 → $100 | +42.59% | Apr 21, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +42.59% | Mar 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +42.59% | Feb 10, 2026 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $61 → $101 | Strong Buy | Maintains | $61 → $101 | +44.02% | Jan 22, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $85 → $100 | Strong Buy | Maintains | $85 → $100 | +42.59% | Jan 21, 2026 |
Financial Forecast
Revenue This Year
460.20M
from 829.45M
Decreased by -44.52%
Revenue Next Year
327.83M
from 460.20M
Decreased by -28.76%
EPS This Year
-3.53
from -0.01
EPS Next Year
-4.28
from -3.53
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 672.0M | 501.9M | ||||||
| Avg | 460.2M | 327.8M | ||||||
| Low | 306.7M | 111.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -19.0% | 9.1% | ||||||
| Avg | -44.5% | -28.8% | ||||||
| Low | -63.0% | -75.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.70 | -1.69 | ||||||
| Avg | -3.53 | -4.28 | ||||||
| Low | -4.36 | -6.57 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.